about
Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cellsLigand-specific dynamics of the androgen receptor at its response element in living cellsClinical and experimental progression of a new model of human prostate cancer and therapeutic approachCrystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosteroneOxidative stress in prostate hyperplasia and carcinogenesisCYP17 inhibitors for prostate cancer therapyTargeting the DNA double strand break repair machinery in prostate cancerA mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental dataRepressive effects of resveratrol on androgen receptor transcriptional activity.Regulation of androgen-responsive transcription by the chromatin remodeling factor CHD8.3, 3'5 Triiodo L thyronine induces apoptosis in human breast cancer MCF-7 cells, repressing SMP30 expression through negative thyroid response elements.Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor.Estrogens and prostatic disease. International Prostate Health Council Study Group.c-Jun NH2-terminal kinase-induced proteasomal degradation of c-FLIPL/S and Bcl2 sensitize prostate cancer cells to Fas- and mitochondria-mediated apoptosis by tetrandrineInactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells.Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cellsHigh progesterone receptor expression in prostate cancer is associated with clinical failure.Estrogens and prostate cancer: etiology, mediators, prevention, and management.A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathwayStepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.The cyclin D1b splice variant: an old oncogene learns new tricks.Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer.Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.Androgen receptor-related diseases: what do we know?Indole-3-Carbinol and Its Role in Chronic Diseases.Hypoxia preconditioning of mesenchymal stromal cells enhances PC3 cell lymphatic metastasis accompanied by VEGFR-3/CCR7 activation.Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer.Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.Differential requirement of SWI/SNF for androgen receptor activity.Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition.Correlation between ERG Fusion Protein and Androgen Receptor Expression by Immunohistochemistry in Prostate, Possible Role in Diagnosis and Therapy.Targeted delivery of an anti-cancer agent via steroid coupled liposomes.Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide.ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells.Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: lack of influence of carcinogen or testosterone treatment.High susceptibility of the ACI and spontaneously hypertensive rat (SHR) strains to 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) prostate carcinogenesis.
P2860
Q24598075-08842417-80C9-40FC-B7B3-77DB787FA02BQ24681534-AC3F2F17-B4A3-42F5-BC04-1DB9787829D9Q24685731-96EB82F6-A757-43FD-8283-0DA141331DFAQ27631345-89B61434-4808-46B4-AC7A-FC2817D0C84BQ28079474-D97A706E-1644-4C2A-98BB-B4FC6A63AEDAQ28298818-B023ABFE-505D-414F-A2A9-740B41134A85Q28744350-5B1D52C1-D8E0-4AFB-A4FA-094716B1504FQ30983127-CA42D7B4-A466-4CD5-B2D7-ABC604E4FAD0Q33509527-5957B8B1-89CF-4292-A35C-736277DC4324Q33874370-E3A3B9EC-8359-4021-84DD-3EF545FEBE98Q33936933-1D089792-F6BF-4342-A93C-20418D2CD4DAQ34011707-60877E69-3C79-4847-81E1-D6EEF23374DCQ34057784-F6C52DF7-C890-48AC-91B3-322DFFE2768EQ34225131-D0537B11-9974-4CAF-9FBC-64C09233B577Q34982106-861CDDA7-9F3D-473D-B906-AD96727290B1Q34991240-159D1C4E-D4BB-4C51-9689-375F87B5FF1BQ35130208-973CFA18-F32C-4C9C-8305-995BF483B863Q35196710-1FD9C4B6-C1AF-4C20-ADB5-C3DF27FB5B44Q35747677-AA2376FC-E99A-487A-B101-1239B6171216Q36218365-26325DEE-93DD-496C-8833-EFC078755240Q36381291-E9407D5A-D6BD-4315-B561-16F8F296F352Q36545151-B51C6616-5B76-4C32-962A-B1258DB5A606Q36721748-0B541E7D-9BC0-45B3-A95B-2F1363A58336Q37322621-0CD7147C-FF8D-48D1-8398-D9B0C8B1E0BDQ37741773-7F84C9D7-39EE-49B9-AFFE-DFA7B5B6A0A9Q37980116-305BD61D-97D5-4077-A926-4E1F26B010E4Q38078285-5B940D9A-3A51-45F3-8585-5F0F8FE9E13DQ38780007-B618C62C-9D55-45BB-9B9A-E13EF8E1A0FDQ38965200-757E695B-4FB1-47DC-8A88-A846BFB227F1Q39111149-A402DFC7-166E-443A-98B9-3412CA1D2ED4Q39376844-1E7E2467-8C25-4443-BA2D-C2D85A2CCF1BQ40503174-C1ACEE12-2BEA-4B92-9C34-AFB74CF8BE75Q40643889-C727CFB2-944C-4DF7-90A7-1BE7EC72EE17Q40650047-544CE0BE-E0FE-46FC-91A6-87F88A4C2AE8Q41242418-AF89D550-2395-4AD3-99B1-F70D47F39214Q43259045-7BF113E6-7DC9-4875-B72B-36D80BF0909EQ43821771-6DBA195C-D73D-4858-A02A-AD1DEA6C674DQ44304000-E1E501EA-40F9-4AE8-95BD-6A31743C60E6Q44412181-833A11E7-4C6B-4A08-BC29-AA9845DF1809Q44651414-4D050C1F-1008-42B9-B161-3F5C95E1028D
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականին հրատարակուած գիտական յօդուած
@hyw
2000 թվականին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Endocrine treatment in prostate cancer
@ast
Endocrine treatment in prostate cancer
@en
Endocrine treatment in prostate cancer
@nl
type
label
Endocrine treatment in prostate cancer
@ast
Endocrine treatment in prostate cancer
@en
Endocrine treatment in prostate cancer
@nl
prefLabel
Endocrine treatment in prostate cancer
@ast
Endocrine treatment in prostate cancer
@en
Endocrine treatment in prostate cancer
@nl
P2860
P3181
P1476
Endocrine treatment in prostate cancer
@en
P2093
K Griffiths
P2860
P3181
P356
10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6
P407
P577
2000-01-01T00:00:00Z